Coherus Reports 75% Confirmed Response Rate For Tagmokitug Combo In First-Line Esophageal Squamous Cell Carcinoma, Interim Phase 1b Data In 8 Evaluable Patients

Loading news article.

Coherus Reports 75% Confirmed Response Rate For Tagmokitug Combo In First-Line Esophageal Squamous Cell Carcinoma, Interim Phase 1b Data In 8 Evaluable Patients | WAPE

Coherus Reports 75% Confirmed Response Rate For Tagmokitug Combo In First-Line Esophageal Squamous Cell Carcinoma, Interim Phase 1b Data In 8 Evaluable Patients

Article summary

Related companies

Analyzed by WAPE AI.

Comments —